You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

This is a single-center

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bile cfDNA of Resectable Biliary Tract Carcinomas

Recruiting
  • This Study Aims to Reveal the Effectiveness, Accuracy, and Feasibility in Bile
  • Next generation sequencing
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Mar 13, 2023

Atopic Dermatitis Trial in East Syracuse, Arlington (ruxolitinib cream)

Recruiting
  • Atopic Dermatitis
  • ruxolitinib cream
  • East Syracuse, New York
  • +1 more
Jan 13, 2023

Multiple Myeloma Myocardial Amyloidosis Were Evaluated by NMR

Enrolling by invitation
  • Multiple Myeloma
  • Amyloidosis Cardiac
  • NMR
  • Xi'an, Shanxi, China
    First Affiliated Hospital of Xian Jiaotong University
Feb 6, 2023

Explore Prognostic Significance of Controlling Nutritional

Completed
  • Heart Failure With Preserved Ejection Fraction
  • +3 more
    • Beijing, Beijing, China
      Beijing Tongren Hospital, Capital Medical University
    Oct 18, 2022

    HER2-positive Metastatic Breast Cancer Trial in Aurora, Madison (Alpelisib, Tucatinib, Fulvestrant)

    Recruiting
    • HER2-positive Metastatic Breast Cancer
    • Aurora, Colorado
    • +2 more
    Dec 29, 2022

    Breast Cancer Trial in Shanghai (A, B, CL1)

    Recruiting
    • Breast Cancer
    • A
    • +8 more
    • Shanghai, Please Select, China
    • +1 more
    Nov 27, 2021

    SARS-CoV-2 Infection Trial in Incheon (CT-P59)

    Completed
    Has Results
    • SARS-CoV-2 Infection
    • CT-P59
    • Incheon, Korea, Republic of
      Incheon Medical Center
    Apr 6, 2022

    Advanced Solid Tumor Trial in Spain, United States (OMTX705, Pembrolizumab)

    Not yet recruiting
    • Advanced Solid Tumor
    • Boston, Massachusetts
    • +7 more
    Sep 16, 2022

    Hypertensive Emergency Trial in Shenzhen (This is a randomized, single-blind, parallel-controlled clinical study with the

    Not yet recruiting
    • Hypertensive Emergency
    • This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.
    • Shenzhen, Guangdong, China
    • +1 more
    Sep 5, 2021

    Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer Trial in Worldwide (Abemaciclib, Trastuzumab, Fulvestrant)

    Active, not recruiting
    Has Results
    • Hormone Receptor Positive Breast Cancer
    • HER-2 Positive Breast Cancer
    • Bakersfield, California
    • +92 more
    Feb 4, 2022

    Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

    Recruiting
    • Newly Diagnosed Peripheral T-cell Lymphoma
    • Duvelisib, Chidamide
    • Wuhan, Hubei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Jul 27, 2023

    This is a Phase Study Conducted in Healthy Volunteers, Osteoporosis Trial (Denosumab)

    Not yet recruiting
    • This is a Phase Study Conducted in Healthy Volunteers
    • Osteoporosis
    • Denosumab
    • (no location specified)
    May 17, 2023

    Bowel Preparation Trial in Nanjing (OSS, OSS+Linzess, PEG-Interferon Alfa)

    Recruiting
    • Bowel Preparation
    • Nanjing, Jiangsu, China
      A single-center, single-blind, randomized controlled clinical st
    Oct 20, 2023

    Gastric Cancer Stage IIIB-IIIC Trial in Shanghai (Pembrolizumab + SOX)

    Recruiting
    • Gastric Cancer Stage IIIB-IIIC
    • Pembrolizumab + SOX
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Sep 7, 2023

    Multiple Myeloma in Relapse Trial in Shenzhen (BCMA/GPRC5D double CAR-T)

    Recruiting
    • Multiple Myeloma in Relapse
    • BCMA/GPRC5D double CAR-T
    • Shenzhen, Guangdong, China
      Shenzhen Qianhai Shekou Free Trade Zone Hospital
    Sep 28, 2023

    Healthy Trial (Test (T) Bilastine, Reference (R) Bilastine)

    Not yet recruiting
    • Healthy
    • Test (T) Bilastine
    • Reference (R) Bilastine
    • (no location specified)
    Oct 19, 2023

    Essential Hypertension Trial (Nerkardou 5 mg & Nerkardou 10 mg)

    Not yet recruiting
    • Essential Hypertension
    • Nerkardou 5 mg & Nerkardou 10 mg
    • (no location specified)
    May 30, 2023

    HER2 Expression and Clinical Pathological Characteristics in

    Recruiting
    • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
    • Collect HER2 expression in prostate cancer patients
    • Jinan, Shandong, China
      Qilu hospital
    Nov 17, 2023

    Potentially Resectable Hepatocellular Carcinoma Trial (FOLFOX-HAIC+Lenvatinib+Envolizumab)

    Not yet recruiting
    • Potentially Resectable Hepatocellular Carcinoma
    • (no location specified)
    Nov 16, 2023

    NSCLC Trial (Tirelizumab;Chemotherapy monotherapy)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Tirelizumab；Chemotherapy monotherapy
    • (no location specified)
    Jul 27, 2023

    Prostate Adenocarcinoma, Prostate Cancer Trial (Transvesical Single Port Robotic Partial Prostatectomy, High-intensity focused

    Not yet recruiting
    • Prostate Adenocarcinoma
    • Prostate Cancer
    • Transvesical Single Port Robotic Partial Prostatectomy
    • High-intensity focused ultrasound (HIFU)
    • (no location specified)
    Nov 3, 2022

    Healthy Trial (ILB-202, Placebo)

    Not yet recruiting
    • Healthy
    • (no location specified)
    May 2, 2023

    Colon Cancer Trial in Qingdao (Chimeric antigen receptor T cell preparation targeting GCC)

    Recruiting
    • Colon Cancer
    • Chimeric antigen receptor T cell preparation targeting GCC
    • Qingdao, Shandong, China
      The Affiliated Hospital of Qingdao University
    May 16, 2023

    Healthy Trial in Zefat (BOL-PK-ST-02A, BOL-PK-ST-02C, BOL-PK-ST-02B)

    Recruiting
    • Healthy
    • Zefat, Israel
      Ziv Medical Center
    Mar 22, 2021

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Zanubrutinib, Polatuzumab vedotin and Rituximab
    • Shanghai, Shanghai, China
      Zhongshan Hospital，Fudan University
    Jul 10, 2023